Abstract
BackgroundDespite improved outcomes in advanced (unresectable or metastatic) melanoma, many patients progress after ICI,1-3 and have low response rates to subsequent therapy.4-7 Lifileucel, a one-time autologous TIL cell therapy, demonstrated...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have